Compare ADMA Biologics Inc (ADMA) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Expensify Inc — how do they compare? ADMA Biologics Inc trades at $9.89 (market cap $2.22B), while Expensify Inc trades at $2.26 (market cap $209.73M). The key difference: ADMA Biologics Inc is far larger — about 10.6× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EXFY | |
|---|---|---|
Market Cap | $2.22B | $209.73M |
Sector | Health | Technology |
52-Week High | $20.38 | $2.69 |
52-Week Low | $7.60 | $0.75 |
Enterprise Value | $2.29B | $149.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Expensify (EXFY) trades at $2.4, down 2.83% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $33.9 million, beating EPS estimates, and raised free cash flow guidance. However, it remains unprofitable on a net income basis, with a negative margin of -11.31% and a high P/E ratio of 258.82, indicating a premium valuation despite losses. Recent news highlights expansion into Europe and AI product enhancements.
The outlook is mixed; operational improvements and AI-driven growth offer upside, but persistent losses and high valuation pose risks. Analyst sentiment is balanced with a 44% buy rating. Investors should weigh the potential for margin expansion against the challenge of achieving sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
